MIRA INFORM REPORT
|
Report Date : |
02.02.2012 |
IDENTIFICATION DETAILS
|
Name : |
FUTURE PHARMACEUTICALS INDUSTRIES SAE |
|
|
|
|
Registered Office : |
Building No. 207,
Street No. 28, 5th Settlement, 4th Territory, New Cairo |
|
|
|
|
Country : |
Egypt |
|
|
|
|
Year of Establishment : |
2008 |
|
|
|
|
Com. Reg. No.: |
23188, Cairo |
|
|
|
|
Legal Form : |
Egyptian Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacture and distribution of pharmaceuticals. |
|
|
|
|
No. of Employees
: |
320 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
US$ 250,000 |
|
Status : |
Satisfactory |
|
Payment
Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30th, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
Egypt |
a2 |
a2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SUMMARY
Company Name : FUTURE PHARMACEUTICALS INDUSTRIES SAE
Country of Origin : Egypt
Legal Form : Egyptian Joint Stock Company
Registration Date : 2008
Commercial Registration Number : 23188, Cairo
Tax Card Number : 245-163-476
Issued Capital : £E 150,000,000
Paid up Capital : £E 150,000,000
Total Workforce : 320
Activities : Manufacture and distribution of pharmaceuticals.
Financial Condition : Undetermined
Payments : Nothing detrimental uncovered
Recommended Credit Limit : US$ 250,000
Person Interviewed : Marwa Sultan, Administration Manager
COMPANY NAME
FUTURE PHARMACEUTICALS INDUSTRIES SAE
company ADDRESS
Registered &
Physical Address
Location : Building No. 207, Street No. 28, 5th
Settlement, 4th Territory
Town : New Cairo
Country : Egypt
Telephone : (20-2) 26180131
Facsimile : (20-2) 26180131
Mobile : (20-11) 6600449
Email : gleithy@future-eg.com
Premises
Subject operates
from a large suite of offices and a warehouse that are rented and located in
the Central Business Area of Cairo.
Branch Office (s)
Location Description
·
1st
Industrial Zone, Plot No. 4G Factory
premises
Badr City
Cairo
Tel: (20-2) 28647581
Fax: (20-2) 28647581
KEY PRINCIPALS
Name Position
·
Dr
Gamal Eddine Nasser Eddine El Leithy Chairman
·
Dr Alaa
Mohamed El Jeyoushi Managing
Director
·
Dr
Joseph Ayat Al Shareef Director
·
Dr
Mostafa Awad Director
·
Dr
Ghada Abdullah Al Shareef Director
·
Dr Tariq
El Attar Marketing
Manager
·
Mohamed
El Sayed Finance
Manager
·
Nasser
Saleh Nasser IT
Manager
·
Marwa
Sultan Administration
Manager
LEGAL FORM & OWNERS
Date of Establishment : 2008, however
full production began in 2011.
Legal Form :
Egyptian Joint Stock
Company
Commercial Reg. No. : 23188, Cairo
Tax
Card No. : 245-163-476
Issued Capital : £E 150,000,000
Paid up Capital : £E 150,000,000
Name of Shareholder
(s)
·
Dr
Gamal Eddine Nasser Eddine El Leithy
·
Dr Alaa
Mohamed El Jeyoushi
·
Dr
Joseph Ayat Al Shareef
·
Dr
Mostafa Awad
·
Dr
Ghada Abdullah Al Shareef
OPERATIONS
Activities: Engaged in the manufacture of
pharmaceuticals.
Import
Countries: Europe and the
Far East.
Subject has a workforce
of approximately 320 employees.
FINANCIAL DATA
Companies
registered in Egypt are not legally required to make their accounts public and
no financial information was released by the company or submitted by outside
sources.
BANKERS
·
National
Societe General Bank
5 Champillion Street
Cairo
Tel: (20-2) 27707000
Fax: (20-2) 27707799
PAYMENT HISTORY
No complaints
regarding subject’s payments have been reported.
GENERAL COMMENTS
Local sources report
that payment obligations are met in a generally timely manner and the operating
history is clear. As such the company is deemed a fair trade risk and the above
credit figure is considered to be within subject’s financial means.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.49.53 |
|
UK Pound |
1 |
Rs.77.95 |
|
Euro |
1 |
Rs.64.66 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.